Abstract 185P
Background
It has been proven that with tumor lesions of the organs of the biliopancreatoduodenal (BPDZ), tumor cells excessively release tumor necrosis factor (TNF-α) in the blood serum and determining their level can assess the activity of the tumor process and the effectiveness of the therapy. Among the causes of mechanical jaundice, the pancreatic head tumor prevailed - 36.1% of patients, in 27.7% of patient's cholestasis was due to a liver gate tumor, in 16.6% - a tumor of the terminal segment of the choledochus, in 13.8% - cancer of the Voter papilla, 5.5% - cancer of the common hepatic duct.
Methods
The study involved 32 patients treated at the General Surgery Department in Tashkent Medical Academy with mechanical jaundice (MJ) with malignant etiology after the application of per-cutaneous-transhepatic cholangiostomy (PTCH). The age of patients ranged from 30 to 74 years, averaging 53.7 ± 3.2 years. There were 19 women and 13 men. In order to remove TNF-α from the body, cholesorption was performed.
Results
The initial concentration of TNF-α in serum averaged 467.43 ± 12.36 (in the norm of 0-5.9 pg/ml). The use of cholesorption contributed to a sharp decrease in the concentration of TNF-α in serum and enhancement of its elimination from the bile. On the 3rd day of observation in the serum, there was a decrease in the concentration of TNF-α by 55.7%. The following days, the serum TNF-α concentration tended to increase and on the 6th day, it averaged 242.05 ± 15.6pg / ml. The next day, serum levels showed a gradual decrease in the concentration of TNF-α and on the 10th day of cholesorption averaged 89.46 ± 7.4-65.49 ± 8.95pg / ml, respectively. On the 14th day of cholesorption in comparison with the initial level, the concentration of TNF-α in the serum decreased 5.5 times.
Conclusions
Thus, the use of cholesorption in patients with MJ of tumor genesis contributes to ridding the body of the pro-inflammatory cytokine TNF-α. The determination of TNF-α in the bile increases the objectivity of the method in assessing the course of the main process and the treatment carried out for BPDZ tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract